January 2018 Double Program

The January Double Program was held at JETRO New York. To down load the event summary, click here.

Click on each topic and speaker to learn more about the program and their bio.

Topic 1: Japan 2018: Revising Medical Fees and Drug Pricing

The Japanese government announced in December discussing the 2018 budget that it will raise the medical treatment prices set under the public health insurance system in 2018. Fees paid to medical institutions for their services are reviewed biennially. Under the government’s budget decision, medical treatment fees paid to hospitals and clinics will rise 0.55 percent. In an effort to restrain the increase in total medical expenses, the government at the same time decided to cut the prices of drugs covered by public health insurance by 1.45 percent, which would impact the pharmaceutical industry.


Takuno Yoshida, First Secretary for Health and Welfare, Embassy of Japan in the United States

Mr. Yoshida has served as the Health and Welfare Attaché at the Embassy of Japan in the US since July 2017. He functions as the POC of the Government of Japan covering a wide range of issues, including healthcare and pension. Mr. Yoshida entered the Ministry of Health, Welfare and Labour (MHLW) in 2003. Prior to joining the Embassy, he was the Deputy Director of the Medical Economics Division, Health Insurance Bureau and in charge of the medical service fee revision of 2016. Since starting his job, Mr. Yoshida held a variety of positions related to issues such as policies for persons with disabilities and labor standards, but about half of his career has been related to healthcare policy. 6 months have passed since he arrived in DC, and Mr. Yoshida is enjoying his American life in Bethesda, MD with his wife and a three year old daughter.


Topic 2: Trends in Oncology

Oncology is a rapidly evolving marketplace with many biopharma companies seeking to develop and commercialize new breakthroughs in science and technology. In recent years, novel immuno-oncology therapeutics have unlocked new levels of durable efficacy and have reshaped therapeutic paradigms and markets landscapes accordingly. Additionally, new modalities such as cell and gene therapies are being applied to the oncology field, creating further complexities for biopharma players to navigate to remain competitive in the space. Peter Lang and Joosung Kim will share from their experience helping diverse biopharma stakeholders navigate these and other trends in the oncology space.


Peter Lang, Managing Director, Life Sciences, Navigant

Mr. Lang has over 20 years of consulting and industry experience working with pharmaceutical and medical device clients.  He has deep expertise in the areas of strategy development and strategic brand planning, product launch, marketing, business development, new product evaluation and post-merger integration.  Peter is a published author and has frequently presented on the topic of strategic brand planning at industry conferences.  Prior to joining Leerink Swann Consulting (and now Navigant Consulting), Peter was a Principal at Archstone Consulting and a Director of Channel Sales at Masimo.  Peter was also a Clinical Trials Manager at Vital Insite and a Software Engineer at Siemens Medical Systems.  Mr. Lang received a Master of Applied Science degree in Biomedical Engineering from the University of Toronto, and a Bachelor of Applied Science degree in Electrical Engineering, also from the University of Toronto.


Joosung Kim, PharmD, Associate Director, Life Sciences, Navigant

Dr. Kim leads the Oncology Working Group at Navigant, which focuses on competitive analysis, opportunity assessments, scientific landscape assessments, and business development strategy in the oncology space. Prior to joining Navigant, Joosung held an industry-based fellowship with the Institute for Pharmaceutical Industry Fellowships in partnership with Bayer. In this role, Joosung served as an analyst in the Global Business Development & Licensing group, and led search and evaluation exercises as well as due diligence initiatives across oncology, cardiopulmonary, women’s health, and neurology therapeutic areas. Joosung received a PharmD with honors from the Ernest Mario School of Pharmacy at Rutgers University, with a focus on clinical pharmacology and pharmacy therapeutics.